Fatty acid modulators for the treatment of diabesity

Drug Discovery Today: Therapeutic Strategies

Volumn 4, Issue 2, 2007, Pages 129-135

  Wertheimer, Stanley J ^a   Bolin, David ^b   Erickson, Shawn ^b   Conde Knape, Karin ^a   Belunis, Charles ^b   Konkar, Anish ^a   Taub, Rebecca ^a   Rondinone, Cristina M ^a  

^a Hoffman La Roche Department of Metabolic Diseases   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ISOPROPYL 3 METHYL 2 [(3 METHYLPIPERIDINE 1 YL)CARBONYL]ISOXAZOLE 5; ACYL COENZYME A DESATURASE; ACYL COENZYME A DESATURASE INHIBITOR; ANTIOBESITY AGENT; ANTISENSE OLIGONUCLEOTIDE; BAY 744113; DIACYLGLYCEROL ACYLTRANSFERASE; DIACYLGLYCEROL ACYLTRANSFERASE 1 INHIBITOR; ENZYME INHIBITOR; HORMONE SENSITIVE LIPASE; HORMONE SENSITIVE LIPASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC OBESITY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DYSLIPIDEMIA; ENERGY EXPENDITURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; FATTY ACID SYNTHESIS; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOGENESIS; NONHUMAN; OBESITY; REVIEW;

EID: 41949088444     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2007.10.002     Document Type: Review

References (46)

1. Mayorek N., et al. Triacylglycerol synthesis in cultured rat hepatocytes. The rate-limiting role of diacylglycerol acyltransferase. Eur. J. Biochem. 182 (1989) 395-400
2. Cases S., et al. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc. Natl. Acad. Sci. U. S. A 95 (1998) 13018-13023
3. Cases S., et al. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase and related family members. J. Biol. Chem. 276 (2001) 38870-38876
4. Farese Jr. R.V., et al. Triglyceride synthesis: insights from the cloning of diacylglycerol acyltransferase. Curr. Opin. Lipidol. 11 (2000) 229-234
5. Yu Y.H., et al. Posttranscriptional control of the expression and function of diacylglycerol acyltransferase-1 in mouse adipocytes. J. Biol. Chem. 277 (2002) 50876-50884
6. Coleman R.A. Diacylglycerol acyltransferase and monoacylglycerol acyltransferase from liver and intestine. Meth. Enzymol. 209 (1992) 98-104
7. Owen M.R., et al. Overt and latent activities of diacylglycerol acytransferase in rat liver microsomes: possible roles in very-low-density lipoprotein triacylglycerol secretion. Biochem. J. 323 (1997) 17-21
8. Shelness G.S., and Sellers J.A. Very-low-density lipoprotein assembly and secretion. Curr. Opin. Lipidol. 12 (2001) 151-157
9. Smith S.J., et al. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat. Genet. 25 (2000) 87-90
10. Chen H.C., et al. Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. J. Clin. Invest. 109 (2002) 1049-1055
11. Chen H.C., et al. Analysis of energy expenditure at different ambient temperatures in mice lacking DGAT1. Am. J. Physiol. 284 (2003) E213-E218
12. Stone S.J., et al. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J. Biol. Chem. 279 (2004) 11767-11776
13. Yu X.X., et al. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 42 (2005) 362-371
14. Chen H.C., et al. Dissociation of obesity and impaired glucose disposal in mice overexpressing acyl coenzyme A:diacylglycerol acyltransferase 1 in white adipose tissue. Diabetes 51 (2002) 3189-3195
15. Yamazaki T., et al. Increased very low density lipoprotein secretion and gonadal gat mass in mice overexpressing liver DGAT1. J. Biol. Chem. 280 (2005) 21506-21514
16. Billheimer J.T., et al. Identification of a potent selective inhibitor of acyl-CoA diacylglycerol acyltransferase 1. Circulation 112 Suppl. II (2005) A1312
17. Monia, B.P. and Graham, M.J. (2004) Modulation of diacylglycerol acyltransferase 1 expression. US20040185559US20040185559 [ISIS Pharmaceuticals]
18. Hirata T., et al. Activation of diacylglycerol O-acyltransferase 1 gene results in increased tumor necrosis factor-alpha gene expression in 3T3-L1 adipocytes. FEBS Lett. 580 (2006) 5117-5121
19. Enoch H.G., et al. Mechanism of rat liver microsomal stearyl-CoA desaturase. Studies of the substrate specificity, enzyme-substrate interactions, and the function of lipid. J. Biol. Chem. 251 (1976) 5095-5103
20. Ntambi J.M., et al. Recent insights into stearoyl-CoA desaturase-1. Curr. Opin. Lipidol. 14 (2003) 255-261
21. Ntambi J.M. Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. J. Lipid Res. 40 (1999) 1549-1558
22. Bene H., et al. Cloning and characterization of the human stearoyl-CoA desaturase gene promoter: transcriptional activation by sterol regulatory element binding protein and repression by polyunsaturated fatty acids and cholesterol. Biochem. Biophys. Res. Commun. 284 (2001) 1194-1198
23. Wang J., et al. Characterization of HSCD5, a novel human stearoyl-CoA desaturase unique to primates. Biochem. Biophys. Res. Commun. 332 (2005) 735-742
24. Wang L., et al. Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Clin. Nutr. 78 (2003) 91-98
25. Corpeleijn E., et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia 49 (2006) 2392-2401
26. Hulver M.W., et al. Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metabol. 2 (2005) 251-261
27. Attie A.D., et al. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J. Lipid Res. 43 (2002) 1899-1907
28. Shiwaku K., et al. Triglyceride levels are ethnic-specifically associated with an index of stearoyl-CoA desaturase activity and n-3 PUFA levels in Asians. J. Lipid Res. 45 (2004) 914-922
29. Cohen P., et al. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 297 (2002) 240-243
30. Chu K., et al. Stearoyl-CoA desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high density lipoprotein cholesterol induced by liver X receptor activation. Mol. Cell Biol. 26 (2006) 6786-6798
31. Lam T.K.T., et al. Brain glucose metabolism control the hepatic secretion of triglyceride rich lipoproteins. Nat. Med. 13 (2007) 171-180
32. Ntambi J.M., et al. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11482-11486
33. Jiang G., et al. Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J. Clin. Invest. 115 (2005) 1030-1038
34. Gutierrez-Juarez R., et al. Critical role of stearoyl-coA desaturase-1 in the onset of diet-induced hepatic insulin resistance. J. Clin. Invest. 116 (2006) 1686-1695
35. Binczek E., et al. Obesity resistance of the stearoyl-CoA desaturase-deficient (scd1-/-)mouse results from the disruption of the epidermal lipid barrier and adaptive thermogenesis. Biol. Chem. 388 (2007) 405-418
36. Fu, J.-M. et al. (2005) Nicotinamide derivatives and their use as therapeutic Agents. US0119251 [Xenon Pharmaceuticals]
37. Li, C.S. et al. (2006) Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase. WO2006130986 [Merck Frosst]
38. Freeman, J. et al. (2007). Discovery of phenoxypiperidines as novel Stearoyl-CoA desaturase inhibitors: From Assay Validation to Lead Development 233rd ACS National Meeting, 25-29 March 2007, Chicago, IL, USA. (MEDI-383)
39. Liu G., et al. Stearoyl CoA desaturase inhibitors: discovery and in vivo evaluation. 233rd ACS National Meeting, 25-29 March 2007. Chicago, IL, USA, (MEDI-232) (2007)
40. Wang M., and Fotsch C. Small-molecule compounds that modulate lipolysis in adipose tissue: targeting strategies and molecular classes. Chem. Biol. 13 (2006) 1019-1027
41. Large V., et al. Hormone-sensitive lipase expression in relation to lipolysis in human fat cells. J. Lipid. Res. 39 (1998) 1688-1695
42. Osuga J., et al. Targeted disruption of hormone-sensitive lipase results in male sterility and adipocyte hypertrophy, but not in obesity. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 787-792
43. Zimmermann R., et al. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 306 (2004) 1383-1386
44. Voshol P.J., et al. Increased hepatic insulin sensitivity with decreased hepatic triglyceride stores in hormone-sensitive lipase deficient mice. Endocrinology 144 (2003) 3456-3462
45. Lowe D.B., et al. In vitro SAR of (5-(2H)-isoxazolonyl) ureas, potent inhibitors of hormone-sensitive lipase. Bioorg. Med. Chem. Lett. 14 (2004) 3155-3159
46. Claus T., et al. Specific inhibition of hormone-sensitive lipase improves lipid profile while reducing plasma glucose. J. Pharmacol. Exp. Ther. 315 (2005) 1396-1402